Sionna Therapeutics (NASDAQ:SION) Receives “Neutral” Rating from Guggenheim

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “neutral” rating reiterated by stock analysts at Guggenheim in a research report issued to clients and investors on Monday, Marketbeat reports.

SION has been the subject of a number of other reports. Wedbush reissued a “neutral” rating and set a $5.00 price objective on shares of Sionna Therapeutics in a research report on Monday. Stifel Nicolaus reissued a “hold” rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research report on Monday. Citigroup downgraded Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Wednesday. Finally, Citizens Jmp cut shares of Sionna Therapeutics from a “mkt outperform” rating to a “market perform” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Price Performance

Sionna Therapeutics stock traded down $46.46 during trading on Monday, reaching $4.58. 27,678,474 shares of the company were exchanged, compared to its average volume of 581,212. The stock’s 50 day simple moving average is $42.35 and its two-hundred day simple moving average is $40.42. The company has a market capitalization of $206.88 million, a P/E ratio of -2.06 and a beta of 1.32. Sionna Therapeutics has a 52-week low of $4.01 and a 52-week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, equities analysts forecast that Sionna Therapeutics will post -2.63 earnings per share for the current year.

Insider Activity

In other news, Director Peter A. Thompson sold 115,844 shares of Sionna Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 403,726 shares of company stock worth $18,259,354. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SION. Deutsche Bank AG raised its holdings in shares of Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after buying an additional 433 shares during the period. Bank of America Corp DE boosted its holdings in Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares during the period. MetLife Investment Management LLC grew its position in Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after acquiring an additional 532 shares in the last quarter. BNP Paribas Financial Markets grew its position in Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $35,000.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Stifel Nicolaus reaffirmed its “hold” rating and set a $7.00 price target, indicating potential upside from the current trading level. However, the unchanged cautious rating suggests the analyst remains concerned about the company’s development risks. Stifel Nicolaus rating update
• Neutral Sentiment: Sionna reported topline results from two cystic fibrosis development programs and said it plans to refocus its pipeline following the clinical setback. The remaining programs could become more important to the company’s valuation, but their prospects remain dependent on future data. Sionna topline data and corporate update
• Negative Sentiment: The company discontinued SION-719 after its mid-stage cystic fibrosis trial failed to produce sufficiently compelling results. Investors viewed the decision as a major setback because it removes a key clinical asset and increases reliance on earlier-stage programs. Sionna cystic fibrosis trial results
• Negative Sentiment: A shareholder-rights law firm announced an investigation into whether Sionna or its executives violated federal securities laws in connection with disclosures about the trial results. The investigation adds legal and reputational risk, although no wrongdoing has been established. Johnson Fistel investigation

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.